AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18471084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-reactivity in dual-positive responders
Number of subjects: 340
Study 18471084 — intervention group
Group type: COMPARATOR
Intervention: Magnitude, frequency, or subclass of PfMSP5 or PvMSP5 IgG antibodies
Number of subjects: 340
Study 18471084 — intervention group
Group type: COMPARATOR
Intervention: Antibody responses and therapeutic response
Number of subjects: 340
Study 16546905 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exposure to mobile phone emissions for 30 min (0.25 W average power)
Number of subjects: 55
Study 16546905 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 55
Study 16546905 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exposure to mobile phone emissions
Number of subjects: 55
Study 12761586 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% BET toothpaste
Number of subjects: 27
Study 12761586 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% SLS and 4% BET toothpaste
Number of subjects: 27
Study 12761586 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% SLS toothpaste
Number of subjects: 27
Study 12761586 — intervention group
Group type: COMPARATOR
Intervention: Reference toothpaste (neither SLS nor BET)
Number of subjects: 27
Study 11171280 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine (0.1 mg/kg)
Number of subjects: 8
Study 11171280 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g)
Number of subjects: 8
Study 11171280 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine plus Vitamin C
Number of subjects: 8
Study 11171280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9505736 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (INVOS 3100)
Number of subjects: 10
Study 9505736 — intervention group
Group type: COMPARATOR
Intervention: Jugular bulb oximetry
Number of subjects: 10
Study 7519691 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril, 2 mg o.d.
Number of subjects: 62
Study 7519691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 3174757 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% nitrous oxide
Number of subjects: 0
Study 3174757 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide
Number of subjects: 0
Study 3174757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7957523 — intervention group
Group type: COMPARATOR
Intervention: Flosequinan (100 mg)
Number of subjects: 8
Study 7957523 — intervention group
Group type: COMPARATOR
Intervention: Xamoterol (200 mg)
Number of subjects: 8
Study 7957523 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (flosequinan + xamoterol)
Number of subjects: 8
Study 7957523 — intervention group
Group type: COMPARATOR
Intervention: Xamoterol
Number of subjects: 8
Study 7957523 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment
Number of subjects: 8
Study 7957523 — intervention group
Group type: COMPARATOR
Intervention: Flosequinan
Number of subjects: 8
Study 384643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (250 mg orally every eight hours for ten days)
Number of subjects: 51
Study 384643 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (250 mg orally every eight hours for ten days)
Number of subjects: 51
Study 384643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor and Amoxicillin
Number of subjects: 51
Study 29374998 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-death experiences (NDEs) reported by burn survivors
Number of subjects: 0
Study 29374998 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and education for health professionals about NDEs
Number of subjects: 0
Study 30103793 — intervention group
Group type: COMPARATOR
Intervention: Tax message
Number of subjects: 21
Study 30103793 — intervention group
Group type: COMPARATOR
Intervention: Subsidy message
Number of subjects: 21
Study 30103793 — intervention group
Group type: EXPERIMENTAL
Intervention: No message (control)
Number of subjects: 21
Study 26296651 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal health education intervention
Number of subjects: 1181
Study 26296651 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care (control)
Number of subjects: 1181
Study 23937319 — intervention group
Group type: EXPERIMENTAL
Intervention: CC + EV (6 mg/day on day 10-14)
Number of subjects: 34
Study 23937319 — intervention group
Group type: COMPARATOR
Intervention: CC + placebo (vitamin B)
Number of subjects: 34
Study 23937319 — intervention group
Group type: EXPERIMENTAL
Intervention: CC + EV
Number of subjects: 34
Study 22364776 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 0
Study 22364776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19027340 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse friction massage (TFM)
Number of subjects: 28
Study 19027340 — intervention group
Group type: COMPARATOR
Intervention: Control (rest period)
Number of subjects: 28
Study 17877850 — intervention group
Group type: EXPERIMENTAL
Intervention: Differences in work goals and information
Number of subjects: 0
Study 17877850 — intervention group
Group type: COMPARATOR
Intervention: Similarities in one respect (either work goals or information)
Number of subjects: 0
Study 15151838 — intervention group
Group type: EXPERIMENTAL
Intervention: V+D+M treatment protocol (levofloxacin, pasiniazide, M. Vaccae)
Number of subjects: 97
Study 15151838 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 15151838 — intervention group
Group type: EXPERIMENTAL
Intervention: V+D+M treatment protocol
Number of subjects: 97
Study 12492253 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron
Number of subjects: 40
Study 12492253 — intervention group
Group type: COMPARATOR
Intervention: 10 mg dexamethasone combined with 60 mg lidocaine
Number of subjects: 40
Study 11273108 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional carbamazepine (200 mg thrice a day)
Number of subjects: 20
Study 11273108 — intervention group
Group type: COMPARATOR
Intervention: Slow-release carbamazepine formulation (200 mg thrice a day)
Number of subjects: 20
Study 11273108 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional carbamazepine
Number of subjects: 20
Study 11273108 — intervention group
Group type: COMPARATOR
Intervention: Slow-release carbamazepine
Number of subjects: 20
Study 7926243 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 10
Study 2571320 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (180 mg)
Number of subjects: 9
Study 2571320 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (180 mg) plus Flurbiprofen (100 mg)
Number of subjects: 9
Study 2571320 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg)
Number of subjects: 9
Study 1206610 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving training groups (8 sessions)
Number of subjects: 41
Study 1206610 — intervention group
Group type: COMPARATOR
Intervention: Play-reading groups (placebo condition)
Number of subjects: 41
Study 1206610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 41
Study 31012824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice pack)
Number of subjects: 16
Study 31012824 — intervention group
Group type: COMPARATOR
Intervention: Control (room temperature sand pack)
Number of subjects: 16
Study 29253401 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% price discount on fruit, vegetables, water, and artificially sweetened soft drinks for 24 weeks
Number of subjects: 20
Study 25549577 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia suture technique (FST)
Number of subjects: 100
Study 25549577 — intervention group
Group type: COMPARATOR
Intervention: Prostar technique
Number of subjects: 100
Study 25549577 — intervention group
Group type: EXPERIMENTAL
Intervention: FST
Number of subjects: 100
Study 25549577 — intervention group
Group type: COMPARATOR
Intervention: Prostar
Number of subjects: 100
Study 24103511 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized individual nutritional therapy (counseling by a dietitian, food fortification, oral nutritional supplements if required)
Number of subjects: 58
Study 24103511 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 58
Study 21545947 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline 30 mg/day for up to 3 days
Number of subjects: 2033
Study 21545947 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo for up to 3 days
Number of subjects: 2033
Study 21545947 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolofylline 30 mg/day
Number of subjects: 2033
Study 21545947 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 2033
Study 19466436 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocarbon cream
Number of subjects: 0
Study 19466436 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex cream
Number of subjects: 0
Study 19466436 — intervention group
Group type: COMPARATOR
Intervention: Untreated skin
Number of subjects: 0
Study 16789458 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0
Study 16789458 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical interventions
Number of subjects: 0
Study 15288334 — intervention group
Group type: EXPERIMENTAL
Intervention: $20 incentive
Number of subjects: 95
Study 15288334 — intervention group
Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 95
Study 15288334 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate preparation
Number of subjects: 95
Study 15288334 — intervention group
Group type: COMPARATOR
Intervention: Delayed preparation
Number of subjects: 95
Study 11040722 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9262415 — intervention group
Group type: EXPERIMENTAL
Intervention: Single matching nontarget
Number of subjects: 0
Study 9262415 — intervention group
Group type: EXPERIMENTAL
Intervention: Single nonmatching nontarget
Number of subjects: 0
Study 9262415 — intervention group
Group type: COMPARATOR
Intervention: Cued location with precue
Number of subjects: 0
Study 8245877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (5 mg/kg/IV/q 12 hours for the first 14 days post-LT) followed by acyclovir (800 mg/po/qid for 14 weeks)
Number of subjects: 218
Study 8245877 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg/po/qid for 16 weeks, starting immediately post-LT)
Number of subjects: 218
Study 8245877 — intervention group
Group type: COMPARATOR
Intervention: Matched historical controls
Number of subjects: 218
Study 3516669 — intervention group
Group type: EXPERIMENTAL
Intervention: Milacemide
Number of subjects: 30
Study 3516669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3516669 — intervention group
Group type: EXPERIMENTAL
Intervention: Milacemide (in patients aged ≤ 25 years)
Number of subjects: 30
Study 31894491 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide followed by alendronate (once-weekly subcutaneous injections of teriparatide 56.5 μg for 72 weeks followed by alendronate for 48 weeks)
Number of subjects: 0
Study 31894491 — intervention group
Group type: COMPARATOR
Intervention: Alendronate monotherapy (alendronate for 120 weeks)
Number of subjects: 0
Study 31894491 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide followed by alendronate
Number of subjects: 0
Study 31894491 — intervention group
Group type: COMPARATOR
Intervention: Alendronate monotherapy
Number of subjects: 0
Study 31032601 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful percutaneous treatment of CTO
Number of subjects: 0
Study 31032601 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO-PCI (percutaneous coronary intervention)
Number of subjects: 0
Study 31032601 — intervention group
Group type: COMPARATOR
Intervention: Unsuccessful revascularization
Number of subjects: 0
Study 31032601 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 0
Study 27914274 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal prostaglandin E2 gel (Prepidil®, dinoprostone) before labor (PGE group, n=90)
Number of subjects: 180
Study 27914274 — intervention group
Group type: COMPARATOR
Intervention: No treatment (unmedicated group, n=90)
Number of subjects: 180
Study 25643895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral hemorrhage (CH) in women
Number of subjects: 13788
Study 25643895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral hemorrhage (CH) in women with JCS0 (alert)
Number of subjects: 13788
Study 25643895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral hemorrhage (CH) in women with JCS1 (disoriented but awake)
Number of subjects: 13788
Study 25643895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral hemorrhage (CH) in women with JCS2 (arousable with stimulation)
Number of subjects: 13788
Study 25643895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral hemorrhage (CH) in women with JCS3 (unarousable)
Number of subjects: 13788
Study 25643895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral infarction (CI) in women with JCS3 (unarousable)
Number of subjects: 13788
Study 23112266 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 126
Study 23112266 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study 21434780 — intervention group
Group type: EXPERIMENTAL
Intervention: Chungkookjang (CKJ) supplementation (26 g/day)
Number of subjects: 60
Study 21434780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19015590 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (ARB)
Number of subjects: 0
Study 19015590 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (CCB)
Number of subjects: 0
Study 16611280 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 90
Study 16611280 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 90
Study 16611280 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 90
Study 12806228 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC)
Number of subjects: 100
Study 12806228 — intervention group
Group type: COMPARATOR
Intervention: Traditional holding (TH)
Number of subjects: 100
Study 11186596 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined walking and conversation treatment
Number of subjects: 65
Study 11186596 — intervention group
Group type: COMPARATOR
Intervention: Assisted walking
Number of subjects: 65
Study 11186596 — intervention group
Group type: COMPARATOR
Intervention: Conversation-only intervention
Number of subjects: 65
Study 8679356 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 3 micrograms kg‐1
Number of subjects: 30
Study 8679356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2068601 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model Intervention
Number of subjects: 842
Study 2068601 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 842
Study 6307178 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg daily for 3 consecutive days every 2 weeks)
Number of subjects: 61
Study 6307178 — intervention group
Group type: COMPARATOR
Intervention: Control group (polychemotherapy and radiotherapy of standard dose or low dose)
Number of subjects: 61
Study 31335776 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Everolimus (EVR)
Number of subjects: 394
Study 31335776 — intervention group
Group type: COMPARATOR
Intervention: Delayed Everolimus (EVR)
Number of subjects: 394
Study 31236143 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR group (7,905 patients)
Number of subjects: 16801
Study 31236143 — intervention group
Group type: COMPARATOR
Intervention: suPAR group (discharged within 24 hours)
Number of subjects: 16801
Study 26183594 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07)
Number of subjects: 320
Study 26183594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 26183594 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (for patients with pre-existing abdominal pain)
Number of subjects: 320
Study 26183594 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for patients with pre-existing abdominal pain)
Number of subjects: 320
Study 26183594 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 320
Study 25925690 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI with SD colonoscopy
Number of subjects: 431
Study 25925690 — intervention group
Group type: COMPARATOR
Intervention: WLI with SD colonoscopy
Number of subjects: 431
Study 25925690 — intervention group
Group type: EXPERIMENTAL
Intervention: NBI with WA colonoscopy
Number of subjects: 431
Study 25925690 — intervention group
Group type: COMPARATOR
Intervention: WLI with WA colonoscopy
Number of subjects: 431
Study 23499231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT) with body image component using Virtual Reality techniques
Number of subjects: 34
Study 23499231 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Treatment (CBT) without body image component
Number of subjects: 34
Study 22164810 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 26
Study 22164810 — intervention group
Group type: COMPARATOR
Intervention: Control (relaxation with a therapist holding feet)
Number of subjects: 26
Study 19937119 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-module intervention session
Number of subjects: 108
Study 19937119 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 108
Study 16374671 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants told they were taking a drug (unconditional expectations)
Number of subjects: 0
Study 16374671 — intervention group
Group type: COMPARATOR
Intervention: Participants told they may or may not be receiving a drug (conditional expectations)
Number of subjects: 0
Study 15498055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 0.5% and phenylephrine 0.5% (regimen I)
Number of subjects: 25
Study 15498055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicamide 1.0% and cyclopentolate 1.0% (regimen II)
Number of subjects: 25
Study 15498055 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1.0% (regimen III)
Number of subjects: 25
Study 15498055 — intervention group
Group type: COMPARATOR
Intervention: Manifest SE
Number of subjects: 25
Study 15498055 — intervention group
Group type: COMPARATOR
Intervention: Regimen I vs Regimen II in children without strabismus
Number of subjects: 25
Study 15498055 — intervention group
Group type: COMPARATOR
Intervention: Regimen I vs Regimen II in children older than 5 years
Number of subjects: 25
Study 10647664 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 57
Study 10647664 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study 7908244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg (5-10 years) or 20 mg (11-15 years) once daily before breakfast
Number of subjects: 40
Study 7908244 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine
Number of subjects: 40
Study 3530644 — intervention group
Group type: EXPERIMENTAL
Intervention: Five bronchodilator drugs (specific drugs not mentioned)
Number of subjects: 10
Study 3530644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer delivery method
Number of subjects: 10
Study 3530644 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhalers delivery method
Number of subjects: 10
Study 3530644 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of medication and delivery method
Number of subjects: 10
Study 30588922 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (group A)
Number of subjects: 30
Study 30588922 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (group B)
Number of subjects: 30
Study 27489153 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one volunteer support for patients with psychosis over a 1-year period, with weekly meetings and engagement in social and recreational activities.
Number of subjects: 0
Study 27489153 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual with a booklet detailing locally available social activities.
Number of subjects: 0
Study 25041486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg
Number of subjects: 40
Study 25041486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 20 mg
Number of subjects: 40
Study 25041486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 40 mg
Number of subjects: 40
Study 25041486 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 40
Study 22302034 — intervention group
Group type: EXPERIMENTAL
Intervention: γ-secretase inhibitor LY450139
Number of subjects: 0
Study 22302034 — intervention group
Group type: EXPERIMENTAL
Intervention: γ-secretase modulator E2012
Number of subjects: 0
Study 20727128 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid IMT measurement using B-mode ultrasound and MIA vascular tools
Number of subjects: 60
Study 18448989 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet gel supplementation
Number of subjects: 20
Study 18448989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no platelet gel)
Number of subjects: 20
Study 18448989 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibia segment with platelet gel
Number of subjects: 20
Study 18448989 — intervention group
Group type: COMPARATOR
Intervention: Tibia segment control
Number of subjects: 20
Study 18448989 — intervention group
Group type: EXPERIMENTAL
Intervention: Humerus segment with platelet gel
Number of subjects: 20
Study 18448989 — intervention group
Group type: COMPARATOR
Intervention: Humerus segment control
Number of subjects: 20
Study 15802445 — intervention group
Group type: EXPERIMENTAL
Intervention: Coil placement in the gastroduodenal artery and around the infusion catheter tip (Group A)
Number of subjects: 78
Study 15802445 — intervention group
Group type: COMPARATOR
Intervention: No coil placement (Group B)
Number of subjects: 78